Sang Young Jeong

Sang Young Jeong is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of stem cell research, particularly in the treatment of cartilage defects. With a total of 2 patents, his work is paving the way for advancements in regenerative medicine.

Latest Patents

Sang Young Jeong's latest patents include innovative methods for treating cartilage defects. One patent focuses on treating cartilage defects with umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) expressing thrombospondin 1 (TSP-1), thrombospondin 2 (TSP-2), interleukin 17B receptor (IL-17BR), and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity. Another patent details a method for selecting stem cells that exhibit high chondrogenic differentiation capability, utilizing the same key factors.

Career Highlights

Sang Young Jeong is currently associated with Medipost Co., Ltd., a company known for its focus on stem cell therapies. His work at Medipost has been instrumental in advancing the understanding and application of stem cell technology in clinical settings.

Collaborations

Throughout his career, Sang Young Jeong has collaborated with notable colleagues, including Yoon-Sun Yang and Won Il Oh. These collaborations have further enriched his research and contributed to the success of his innovative projects.

Conclusion

Sang Young Jeong's contributions to stem cell research and his innovative patents are making a significant impact in the field of regenerative medicine. His work continues to inspire advancements that may lead to effective treatments for cartilage defects and beyond.

Profile summary based on public USPTO records.